Gilgamesh Pharmaceuticals

Focus: Gilgamesh Pharmaceuticals is a Series B-stage biotech focused on psychedelic medicines for neuropsychiatric disorders, headquartered in New York. The company is positioned in an emerging therapeutic area with significant clinical and commercial potential.

Neurology Psychiatry

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Funding Stage

SERIES B

Open Jobs

About Gilgamesh Pharmaceuticals

AI assessmentNot Hiring

No open roles listed right now. Follow Gilgamesh Pharmaceuticals to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

2 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

GM-1020

Major Depressive Disorder

Phase 2

Clinical Trials (1)

NCT06309277A Clinical Study to Evaluate of Single and Multiple Oral Doses of GM-1020 in Patients With MDD

Phase 2

Help build intelligence for Gilgamesh Pharmaceuticals

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Early-stage opportunity in the rapidly expanding psychedelic medicines space, a therapeutic area with substantial FDA interest and clinical validation potential
Two Phase 2 programs (GM-1020 and GM-2505) in Major Depressive Disorder targeting a massive unmet medical need with limited current options
Series B funding stage allows for meaningful equity upside before later-stage dilution, with significant room for career growth as company scales

Watch Out For

Pre-revenue company with no marketed products creates execution risk; cash runway and funding trajectory are unknown
Currently zero open job postings suggests potential hiring freeze, slow growth phase, or limited near-term expansion plans
Psychedelic medicines remain federally controlled substances with regulatory uncertainty that could impact development timelines and commercialization strategy

Generated by Claude from Gilgamesh Pharmaceuticals's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

GM-2505

Major Depressive Disorder

Phase 2

Clinical Trials (1)

NCT06236880A Phase 2a Study to Evaluate the Safety and Tolerability of GM-2505 in Patients With MDD

Phase 2

Open Jobs (0)

No open positions listed yet.

Interview Prep Quick Facts

Portfolio: 2 clinical trials

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo